CureVac's mRNA Coronavirus Shot Boasts Refrigerated Storage - COVID-19 Clinical Trial
Breaking News | COVID-19

CureVac’s mRNA Coronavirus Shot Boasts Refrigerated Storage

While Pfizer’s COVID-19 vaccine turned in strong early efficacy numbers and NIAID director Anthony Fauci said he expects similar figures from Moderna, the new class of mRNA shots mostly comes with stringent storage requirements that raise logistical hurdles for a broad rollout. Except the program under development at CureVac, which now reports its candidate is stable for up to three months at refrigerator temperatures. Dubbed CVnCoV, CureVac’s shot can also be kept for up to 24 hours at room temperature, further reducing burdens for vaccination efforts, the company said.

The German biotech, which advanced to phase 2a testing in late September, is “very encouraged by the emerging stability profile,” of its vaccine candidate, chief production officer Florian von der Mülbe said in a statement. The profile “has the potential both to enable decentralized storage and to significantly facilitate large-scale vaccination efforts during the current pandemic,” he added.


Pfizer-BioNTech COVID Vaccine Data ‘open the floodgates’ for mRNA in Infectious Disease

The entire scientific community is cheering on Pfizer and BioNTech’s early COVID-19 vaccine data. Beyond the obvious boon for fighting the pandemic, the 90% efficacy result showed mRNA shots really can work.

For an entirely new technology that hasn’t seen a single approved product, that’s a big deal; the coronavirus showing proved it can be quickly pivoted for a pandemic pathogen. But its usefulness in other diseases? That could be a different story, two industry watchers figure. The early success of a COVID vaccine is going to “open the floodgates” of mRNA application especially in infectious disease, SVB Leerink analyst Daina Graybosch, who covers BioNTech, said in an interview.

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.